<DOC>
	<DOCNO>NCT00895076</DOCNO>
	<brief_summary>The primary objective evaluate extent systemic exposure dexamethasone bioavailability follow single application dexamethasone iontophoretic transdermal patch healthy volunteer . The secondary objective evaluate systemic topical safety dexamethasone iontophoretic transdermal patch dexamethasone intramuscular ( IM ) injection .</brief_summary>
	<brief_title>Study Compare Pharmacokinetics Dexamethasone Iontophoretic Patch Dexamethasone Injection</brief_title>
	<detailed_description />
	<mesh_term>Tennis Elbow</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Men woman age 18 Years 45 Years Must Body Mass Index ( BMI ) 18 29 kg/m2 , inclusive . Must , investigator 's opinion , clinically significant disease determine medical psychiatric history , physical examination , vital sign , and/or laboratory evaluation conduct screen visit clinic admission would interfere evaluation safety pharmacokinetics . Must negative screen HbsAg , HCVAb , HIVAb , history positive result . Female subject may include surgically sterile 2 year post menopausal , negative serum pregnancy test screening . Female subject child bear potential perimenopausal subject may include negative serum pregnancy test screen admission clinic Day 1 , agree use medically accept method birth control ( e.g. , barrier method spermicide , oral contraceptive , abstinence ) agree continue use method duration trial . Must nonsmoker , define smoked tobacco , use chew tobacco , use nicotinecontaining product smoke cessation 6 month prior screen . Must able communicate effectively study personnel . Must agree remain study facility overnight approximately five consecutive day night . Is female subject pregnant , breastfeeding , plan pregnancy study . Has clinically significant unstable medical abnormality , chronic disease , significant neurological ( include seizure cognitive disorder ) , hepatic , renal , endocrine , cardiovascular , gastrointestinal , pulmonary , metabolic disease , abnormality could interfere PK evaluation study drug . Particular attention pay exclude subject risk consequence systemic corticosteroid exposure , diabetes poorly control hypertension . Has clinically significant illness within 30 day Screening . Use prescription medication ( hormonal contraceptive ) within 14 day overthecounter ( OTC ) medication ( exception ibuprofen acetaminophen ) within 7 day randomization intend use prescription OTC medication study may interfere evaluation study drug . Use topical cream , lotion oil patch application site within 2 week treatment administration first period throughout study . Use steroid , include topical steroid , within 4 week treatment administration first period throughout study . Intake grapefruit product , food , herbal product overthecounter prescription medication may interact CYP450 enzyme system 7 day prior treatment administration first period completion endofstudy procedure . Has ingest alcohol within 24 hour admission ( Day 1 ) throughout study . Has history significant allergy hypersensitivity study drug component iontophoretic transdermal patch use study , include allergy sensitivity bandage adhesives sodium bisulfate . Has follow exclusionary clinical laboratory result : 1 . Hemoglobin le 12.0 g/dL 2 . Serum creatinine great 2.0 mg/dL 3 . Abnormal liver function test ( serum glutamic oxaloacetic transaminase [ SGOT ] , also call aspartate transaminase [ AST ] ; serum glutamic pyruvic transaminase [ SGPT ] , also call alanine transaminase [ ALT ] twice upper limit normal ) 4 . Elevated serum bilirubin 2 time upper limit normal Any blood donation significant blood loss within 90 day treatment administration first period . Any plasma donation within 7 day randomization . Has sensory dysfunction , skin irritation , sensitivity disease , tattoo may opinion investigator interfere assessment topical effect site patch application . Has history alcohol abuse , illicit drug use , significant mental illness , physical dependence opioid , history drug abuse addiction within 12 month study enrollment . Has develop positive urine drug screen , include ethanol , cocaine , tetrahydrocannabinol , barbiturate , amphetamine , benzodiazepine , opiate . Use investigational drug within 30 day five halflives ( whichever longer ) treatment administration first period , plan use investigational drug ( study drug ) study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>